Protease-activated receptor 1 (PAR1) is the prototypical member of a family of G-protein-coupled receptors that mediate cellular responses to thrombin and related proteases. Thrombin irreversibly activates PAR1 by cleaving the amino-terminal exodomain of the receptor, which exposes a tethered peptide ligand that binds the heptahelical bundle of the receptor to affect G-protein activation. Here we report the 2.2 Å resolution crystal structure of human PAR1 bound to vorapaxar, a PAR1 antagonist. The structure reveals an unusual mode of drug binding that explains how a small molecule binds virtually irreversibly to inhibit receptor activation by the tethered ligand of PAR1. In contrast to deep, solvent-exposed binding pockets observed in other peptide-activated G-protein-coupled receptors, the vorapaxar-binding pocket is superficial but has little surface exposed to the aqueous solvent. Protease-activated receptors are important targets for drug development. The structure reported here will aid the development of improved PAR1 antagonists and the discovery of antagonists to other members of this receptor family.
Protease-activated receptor 1 (PAR1) is the prototypical member of a family of G-protein-coupled receptors that mediate cellular responses to thrombin and related proteases. Thrombin irreversibly activates PAR1 by cleaving the amino-terminal exodomain of the receptor, which exposes a tethered peptide ligand that binds the heptahelical bundle of the receptor to affect G-protein activation. Here we report the 2.2 Å resolution crystal structure of human PAR1 bound to vorapaxar, a PAR1 antagonist. The structure reveals an unusual mode of drug binding that explains how a small molecule binds virtually irreversibly to inhibit receptor activation by the tethered ligand of PAR1. In contrast to deep, solvent-exposed binding pockets observed in other peptide-activated G-protein-coupled receptors, the vorapaxar-binding pocket is superficial but has little surface exposed to the aqueous solvent. Protease-activated receptors are important targets for drug development. The structure reported here will aid the development of improved PAR1 antagonists and the discovery of antagonists to other members of this receptor family.
Protease-activated receptors (PARs) are G-protein-coupled receptors (GPCRs) that mediate cellular responses to specific proteases 1,2 . The coagulation protease thrombin activates the prototypical PAR, PAR1, by specific cleavage of the N-terminal exodomain of the receptor to generate a new N terminus. This new N terminus then functions as a tethered peptide agonist that binds intramolecularly to the seventransmembrane helix bundle of the receptor to affect G-protein activation 1,3-8 (Fig. 1a ). In adult mammals, the four members of the PAR family link tissue injury and local generation of active coagulation proteases to cellular responses that help to orchestrate haemostasis, thrombosis, inflammation and perhaps tissue repair 2, 9 . PARs may also participate in the progression of specific cancers 10, 11 .
In contrast to a typical receptor-agonist binding interaction, the interaction of PAR1 with its activator, thrombin, is that of a protease substrate, with thrombin binding transiently to the receptor, cleaving it, then dissociating 1,3-7,12 . Proteolytic unmasking of the tethered peptide agonist of the receptor is irreversible, and although a free synthetic hexapeptide with the amino acid sequence of the tethered agonist (SFLLRN) can activate the receptor with half-maximum effective concentration (EC 50 ) values in the 3-10-mM range, the local concentration of the tethered agonist peptide is estimated to be about 0.4 mM. Accordingly, PAR signalling must be actively terminated [13] [14] [15] and, unlike most other GPCRs that can go though many rounds of activation by reversible diffusible hormones and neurotransmitters, PARs are degraded after a single activation 6, [13] [14] [15] [16] [17] . Identification of effective PAR antagonists has been challenging because low molecular mass compounds must compete with the very high local concentration of the tethered agonist generated by proteolytic cleavage.
Vorapaxar is a highly specific, virtually irreversible PAR1 antagonist 18 (Supplementary Fig. 1 ). In a phase III trial, vorapaxar protected patients against recurrent myocardial infarction at a cost of increased bleeding 19, 20 . Given the latter, an antagonist that is reversible in the setting of bleeding might be desirable. Although the very slow dissociation rate of vorapaxar from PAR1 probably accounts for its ability to with antagonist vorapaxar. a, Thrombin cleaves the PAR1 N terminus and exposes a new N-terminal peptide, SFLLRN, which can bind to and activate the transmembrane core of PAR1. PAR1 can activate several G proteins including G i , G 12/13 and G q . b, Overall view of the human PAR1 structure and the extracellular surface. The receptor is shown as blue ribbon and vorapaxar is shown as green spheres. Monoolein is shown in orange, water in red. The disulphide bond is shown as a yellow stick. c, Surface view of the ligand-binding pocket viewed from two different perspectives. The vorapaxar-binding pocket is close to the extracellular surface but not well exposed to the extracellular solvent. inhibit receptor activation by its tethered agonist peptide, it may be possible to develop a drug with an off rate slow enough to block signalling but fast enough to allow useful reversal after cessation of drug.
In an effort to advance our understanding of PAR1 structure and function and to provide a foundation for discovery of new agents to advance the pharmacology of PARs, we obtained the crystal structure of vorapaxar-bound human PAR1.
Crystallization of human PAR1
To facilitate crystallogenesis, T4 lysozyme (T4L) was inserted into intracellular loop 3 (ICL3) in human PAR1, the N-linked glycosylation sites in ECL2 were mutated 21 , and the N-terminal exodomain was removed by site-specific cleavage at a tobacco etch virus (TEV) protease site introduced between amino acids 85 and 86 (ref. 4; Supplementary Fig. 2 ). The structure of human PAR1-T4L bound to vorapaxar was determined to 2.2 Å by merging diffraction data sets from 18 crystals grown in the lipidic cubic phase (Supplementary Figs 3 and 4). Details of data collection and structure refinement are listed in Supplementary Table 1. PAR1 has the expected seven-transmembrane segment bundle ( Fig. 1b ). There are several lipid molecules assigned as monoolein from lipidic cubic phase in the structure (Fig. 1b ), but no ordered cholesterol molecules were observed. The remaining N-terminal fragment Arg 86-Glu 90 and a part of the ICL2 from Gln 209 to Trp 213 are not modelled in the structure because of the weak electron density. There is no clear electron density for residues after Cys 378, and no helix 8 is observed after transmembrane segment 7 (TM7) in the structure. Whether this reflects a lack of a helix 8 in PAR1 in its native state or conditions in the crystal is not known.
Cys 175 3. 25 in helix III and Cys 254 in extracellular loop 2 (ECL2) form a conserved disulphide bond (Figs 1b and 2a ). Amino-terminal to Cys 254, ECL2 loops outwards in two anti-parallel b strands. This structural feature is found in other peptide receptors, including the CXCR4 receptor and the opioid receptors [22] [23] [24] [25] , despite absence of amino acid sequence homology among these receptors in ECL2 ( Supplementary Fig. 5 ). In contrast to the open, solvent-exposed binding pocket observed in the m-opioid receptor (MOR) and other peptide receptors, access to the vorapaxar-binding pocket is restricted by the central location of ECL2 ( Fig. 1 and Supplementary Figs 5 and 6), which almost completely covers the extracellular-facing surface of vorapaxar. ECL2 is anchored in this position by hydrogen bonds between His 255 in ECL2 and Tyr 353 7.35 in TM7, and between Asp 256 in ECL2 and Tyr 95 in the N terminus ( Supplementary  Fig. 6 ), and by extensive interactions with vorapaxar ( Fig. 2) . The covered vorapaxar-binding pocket in PAR1 more closely resembles rhodopsin and the lipid-activated sphingosine-1-phosphate receptor (S1P 1 ) than other peptide-activated GPCRs ( Supplementary Fig. 5 ).
Divergence of PAR1 from other family A GPCRs
Members of the family A GPCRs share a set of conserved amino acids that are thought to be important in signal transduction 26, 27 . Specific residues in the highly conserved FXXCWXP motif (in which X denotes any amino acid) in TM6, and the NPXXY motif in TM7 undergo structural rearrangements during activation of the b 2 adrenergic receptor (b 2 AR) ( Fig. 3b, d ). However, based on a phylogenetic analysis of amino acid sequences 28 , PAR1 is a more distant relative of the family A GPCRs that have been crystallized thus far. PAR1 belongs to the d-subfamily, which includes the glycoprotein receptors, the purinergic receptors and the olfactory receptors 28 . The tryptophan residue in FXXCW 6.48 XP proposed to act as a toggle switch during activation in some GPCRs 28 is replaced by Phe 6.48 in all PARs (Fig. 3a ). Phe 6.44 , also highly conserved in family A GPCRs, is Phe 6.44 in PAR1, but Tyr 6.44 in PAR2 and Ala 6.44 in PAR4. When comparing inactive and active states of the b 2 AR, changes in packing interactions involving Pro 5.50 , Ile 3. 40 and Phe 6.44 seem to have a role in structural changes needed to accommodate G-protein binding [29] [30] [31] . Packing interactions of the corresponding residues Pro 282 5.50 , Ile 190 3. 40 and Phe 322 6.44 in the PAR1 differ from those in both active and inactive b 2 AR structures ( Fig. 3b ). Taken together, these differences suggest that PAR1 may differ from other family A GPCRs in the mechanism by which signals propagate from the extracellular peptide-binding interface to the cytoplasmic domains that interact with G proteins and other signalling molecules.
The NP 7.50 XXY motif at the end of helix VII observed in most family A GPCRs is DP 7.50 XXY in PAR1. This region undergoes structural rearrangement after activation of the b 2 AR. In PAR1, Asp 367 7.49 and Tyr 371 7.53 form hydrogen bonds with residues in TM2 and TM1 (Fig. 3c ). The hydrogen-bonding network associated with Asp 367 7.49 is extensive and includes several water molecules and a putative sodium ion. Na 1 , rather than a water molecule, was assigned to this region of electron density as it has five oxygen neighbours and short distances to its oxygen ligands (average refined distance 2.4 Å ), both consistent with known Na 1 -oxygen interactions 32 , and it interacts with two acidic side chains that, assuming deprotonated states, would repel one another without charge neutralization provided by the Na 1 . The sodium ion also interacts with a conserved Asp 148 2.50 in TM2 and Ser 189 3.39 in TM3, with two water molecules nearby ( Fig. 3c ). Na 1 is an allosteric modulator for several family A GPCRs such as the a 2A adrenergic receptor, A 2A adenosine receptor, mand d-opioid receptors and D 2 dopamine receptor [33] [34] [35] [36] [37] . The conserved Asp 2.50 is necessary for sodium sensitivity of the a 2A adrenergic receptor 37 and D 2 dopamine receptor 36, 38 . In PAR1, Asp 367 7.49 might be expected to form a stronger hydrogen-bonding network and sodium coordination site than asparagine residues found in most other family A GPCRs. This more stable network may contribute to the unusual position of the cytoplasmic end of TM7 that is displaced inward towards TM2. This position is more similar to the F271 F271  Y183 Y183   Y353 Y353   A349 A349   H336 H336   L258 L258   TM6 TM6   TM5 TM5   TM7 TM7   TM4 TM4   TM3 TM3 H255 H255 ECL2 ECL2 Y183   Y353   A349   H336   L258   TM6   TM5   TM7   TM4   TM3 
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active b 2 AR bound with either nanobody 80 or heterotrimeric G protein 29, 31 (Fig. 3d ).
Structural insights into binding properties of vorapaxar
Vorapaxar binds in an unusual location very close to the extracellular surface of PAR1. By contrast, ligands for other GPCRs penetrate more deeply into the transmembrane core ( Fig. 1 and Supplementary Figs 5  and 7 ). The vorapaxar-binding pocket, composed of residues from TM3, TM4, TM5, TM6 and TM7 as well as ECL2 and ECL3, forms a tunnel across the receptor with one end open between TM4 and TM5 and the other between TM6 and TM7 occupied by the ethyl carbamate tail of vorapaxar (Figs 1 and 2) . There is only a small opening in the extracellular surface between ECL2 and ECL3. Details of interactions between vorapaxar and PAR1 are illustrated in Fig. 2 and Supplementary Fig. 8 .
Vorapaxar shows high selectivity for human PAR1 over human PAR2 and PAR4, and mouse PAR1 in functional assays (Supplementary Fig. 9A, B ). The structural basis for this selectivity is not readily apparent from the crystal structure. Nearly all the residues that interact with vorapaxar in human PAR1 are conserved in human PAR2, human PAR4 and mouse PAR1 ( Supplementary Fig. 10 ). Residues Leu 262 and Leu 263, which are involved in weak hydrophobic interactions with vorapaxar in human PAR1, are alanine and asparagine, respectively, in human PAR4, and Leu 263 is a methionine in mouse PAR1 ( Fig. 2c and Supplementary Fig. 10 ). These differences by themselves would not be expected to explain the high selectivity of vorapaxar. However, Leu 262 and Leu 263 pack against other amino acids that have more extensive interactions with vorapaxar. Leu 262 interacts with His 255 in ECL2 and Leu 263 interacts with Phe 271 5.39 at the top of TM5 and Tyr 337 6.59 at the top of TM6 ( Fig. 2c ). These interactions may influence ligand-binding selectivity indirectly by contributing to the overall structure and stability of the binding pocket. Amino acid differences between PAR1, PAR2 and PAR4 more distant from the ligand-binding pocket may also contribute to subtype-specific binding of vorapaxar. Phe 274 5.42 is Leu in PAR2 and PAR4, and Phe 278 5.46 is Val in PAR2 and Gly in PAR4. Although neither Phe 274 5.42 nor Phe 278 5.46 directly contact vorapaxar, Phe 278 5.46 packs against Phe 274 5.42 , which in turn packs against Phe 271 5.39 in the binding pocket ( Fig. 2c ).
In human PAR2 and PAR4, ECL3 connecting TM6 and TM7 is one residue shorter than it is in PAR1 ( Supplementary Fig. 9C ). Tyr 337 6.59 at the carboxy-terminal end of TM6 forms a strong hydrogen bond with vorapaxar ( Fig. 2 and Supplementary Fig. 9D ). Another residue, Tyr 353 7.35 , which forms the base of the ligandbinding pocket together with Tyr 183 3. 33 , is located at the Nterminal end of TM7 ( Fig. 2 and Supplementary Fig. 9D ). A shorter ECL3 in human PAR2 and PAR4 may change the relative position of these amino acids, thereby altering the overall geometry of the binding pocket. Although the length of ECL3 in mouse and human PAR1 is the same, four of the eight amino acids are different ( Supplementary  Fig. 9C ). These differences may affect the structure of ECL3 and thereby influence interactions between vorapaxar in Tyr 337 6.59 and Tyr 353 7.35 . Alternatively, these differences could have an effect on the mechanism by which vorapaxar gains access to the binding pocket. 
ARTICLE RESEARCH

Structural insights into vorapaxar inhibition of PAR1
Although this structure is compatible with the very slow dissociation rate of vorapaxar, it does not provide insight into the mechanism by which vorapaxar or an agonist peptide gains access to the binding pocket. None of the three openings to the vorapaxar-binding pocket is large enough to accommodate the passage of the ligand. We thus wondered whether the unliganded receptor might have a more open structure, similar to that observed for opioid receptors, with unique interactions between vorapaxar and PAR1 causing an otherwise open binding pocket to close after vorapaxar binding. To investigate this issue, we performed long-timescale molecular dynamics simulations of PAR1 with and without vorapaxar bound. Intriguingly, removal of the ligand did not lead to a more open binding pocket, but instead to one that was even more closed (Fig. 4a, b , Supplementary Fig. 11 and Supplementary Table 2 ). The extracellular end of TM6 moved about 4 Å inward towards TM4, bringing ECL3 in full contact with ECL2 and completely occluding the binding pocket. By contrast, in a similar study on the MOR, the binding pocket remained open when the ligand was removed ( Supplementary Fig. 11 ). The collapse of the vorapaxar-binding pocket may reflect the fact that both vorapaxar and its binding pocket are uncharged, whereas in the opioid receptors and many other family A GPCRs, the charged residue Asp 3.32 helps to keep the binding pocket hydrated after the ligand is removed.
It is interesting to speculate that vorapaxar, a highly lipophilic molecule, may access the binding pocket through the lipid bilayer, possibly between TM6 and TM7. This is similar to the binding mode proposed for retinal to rhodopsin and the lipid sphingosine-1phosphate (S1P) to the S1P 1 receptor 39, 40 (Supplementary Fig. 5 ).
To understand the ability of vorapaxar to inhibit agonist binding and activation, we examined the functional consequences of mutating four aromatic amino acids that form strong interactions with vorapaxar: Tyr 183 3. 33 , Tyr 353 7.35 , Phe 271 5. 39 and Tyr 337 6.59 (Fig. 2a, b and Supplementary Fig. 3C ). Three of these (Tyr 353 7.35 , Phe 271 5.39 and Tyr 337 6.59 ) assume substantially different positions in simulations of unliganded PAR1 (Fig. 4a ). Tyrosine residues Tyr 183 3.33 in TM3 and Tyr 353 7.35 in TM7 are linked to each other by a hydrogen bond and form the base of the binding 'tunnel', and are part of a hydrophobic cage that surrounds the ligand. Tyr 353 7.35 also forms a hydrogen bond with His 255, the most deeply buried amino acid in ECL2 ( Fig. 2a and Supplementary Fig. 6 ). This interaction of His 255 with Tyr 353 7.35 contributes to the closed conformation of ECL2 over the ligand-binding pocket. Phe 271 5.39 interacts with the fluorophenyl ring and Tyr 337 6.59 forms a strong hydrogen bond with the pyridine ring of vorapaxar.
Mutation of Tyr 337 6.59 to phenylalanine and Tyr 353 7.35 to alanine led to a reduction in cell surface expression, making it difficult to interpret the associated reduction in agonist peptide activation (Fig. 4c, d) . Mutation of Phe 271 5.39 to alanine was associated with enhanced cell surface expression, but reduced activation by agonist peptide. There was little effect of this mutation on maximal inhibition by vorapaxar. Although not conclusive, this result suggests that Phe 271 5.39 may have a role in both peptide and vorapaxar binding. Of interest, mutation of Tyr 183 3.33 exhibited enhanced response to the agonist peptide and loss of inhibition by vorapaxar (Fig. 4c ). This result suggests a possible role for Tyr 183 3.33 in maintaining the receptor in an inactive state and indicates that interactions between Tyr 183 3. 33 and vorapaxar may further stabilize an inactive conformation.
Activation of PAR1 by the agonist peptide
Our structure is consistent with data from mutagenesis studies that suggest that the PAR1-tethered agonist peptide may activate the heptahelical bundle of the receptor by interacting with superficial structures rather than penetrating deeply into the transmembrane core 8, [41] [42] [43] [44] [45] . Glu 260, a solvent-exposed residue in ECL2 in both vorapaxar-bound and unliganded PAR1 (Fig. 5 ), is of particular interest, as evidence from mutagenesis studies suggests an interaction with Arg 46 in the tethered peptide SFLLRN 8, 44 . Substitution of Glu 260 with arginine markedly reduces activation of PAR1 by a peptide with the native tethered ligand sequence (SFLLRN) but facilitates activation by SFLLEN. Arginine substitution of Glu 264, which is surface-exposed and near Glu 260 in the structure, also facilitates activation by SFLLEN.
Mutation of other residues near the extracellular surface, including Leu96Ala (N terminus), Asp256Ala (ECL2) and Glu347 
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agonist. However, these mutations have only a small effect on agonist peptide binding, with only Asp256Ala resulting in a more than tenfold loss of binding affinity 43 . The positions of these residues do not change substantially when comparing vorapaxar-bound and unliganded PAR1 ( Fig. 5b ). Of interest, only Glu 347 7.29 is surface exposed (Fig. 5a, b ), suggesting that Leu 96 and Asp 256 may not interact directly with the agonist peptide or that these amino acids are more exposed than would appear from the molecular dynamics model of the unliganded receptor.
In the inactive structure, Asp 256 forms a hydrogen bond with Tyr 95 and helps to stabilize interactions between the C-terminal end of the N terminus and ECL2 (Fig. 5a) . Interestingly, substitution of human PAR1 sequence Asn 259-Ala 268, the region of ECL2 implicated in tethered ligand binding, with the cognate Xenopus ECL2 sequence results in an approximately tenfold increase in basal activity 46 . Figure 5c shows the position of amino acids that differ between human and Xenopus receptors in ECL2 in both the crystal structure and the unliganded molecular dynamics simulation. The superficial location of these activating mutations suggests that very superficial interactions between the tethered agonist peptide and the extracellular loops may be sufficient to activate PAR1. Taken together, these mutagenesis studies suggest that the PAR1 agonist peptide may activate PAR1 by binding more superficially than do agonist peptides for opioid receptors. Alternatively, the tethered peptide may bind in a sequential manner, initially to the extracellular loops but penetrating more deeply into the core of the receptor through a sequence of conformational intermediates.
Conclusion
The unusual mode of activation and the paucity of pharmacological tools have made PAR1 one of the more challenging GPCRs to characterize and a difficult target for drug development. The crystal structure offers insights into the very high affinity interaction with the antagonist vorapaxar. This structure will provide a template for the development of PAR1 antagonists with better drug properties and the development of antagonists for other PAR subtypes to probe their biological roles. The mechanism of activation of PAR1 remains poorly understood. Molecular dynamics simulations of an unliganded receptor together with the location of amino acids known to influence agonist peptide activity suggest that activation of PAR1 by its agonist peptide may involve superficial interactions with extracellular loops. Future efforts will focus on an active-state structure of PAR1 bound to its tethered agonist peptide.
METHODS SUMMARY
The human PAR1-T4L fusion protein was expressed in Sf9 insect cells and purified by nickel-affinity chromatography, Flag M1 antibody affinity chromatography followed by size exclusion chromatography. PAR1-T4L crystals were grown using the in meso crystallization method. The diffraction data were collected from 18 crystals at the GM/CA@APS beamline in the Argonne National Laboratory. The structure was solved by molecular replacement and refined in Phenix. Refinement statistics are provided in Supplementary Table 1 . All-atom molecular dynamics simulations were performed on Anton 47 with lipids and water molecules represented explicitly. Phosphoinositide hydrolysis assays were done in Cos7 cells transfected with wild-type and mutant PAR1. More details are provided in Methods. near the extracellular surface have been shown to reduce activation of PAR1 by the free agonist peptide. Among them only Glu 260 is completely exposed to the solvent, whereas Asp 256 is the most deeply buried, forming a hydrogen bond with residue Tyr 95. Although none of these amino acids forms part of the vorapaxar-binding pocket, Asp 256 forms a hydrogen bond with Tyr 95 that may stabilize ECL2 over the vorapaxar-binding pocket. Vorapaxar is shown in green. b, c, Superimposition of the unliganded molecular dynamics simulation model (grey) with the ligand-bound crystal structure (blue). In b, Residues Glu 260, Asp 256, Leu 96 and Glu 347 7.29 , which are important for agonist peptide signalling, are in similar positions in both structures. c, The positions of residues that differ between human and Xenopus PAR1 in ECL2. Substitution of these residues in human PAR1 with corresponding residues from Xenopus PAR1 results in increased basal activity.
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METHODS PAR1-T4L expression and purification. To facilitate crystallogenesis, a human PAR1 construct was generated with several modifications. A TEV proteaserecognition site was introduced after residue Pro 85, two N-linked glycosylation sites in ECL2 were removed by mutation (Asn250Gly and Asn259Ser), and the C terminus was truncated after residue Ser 395. T4L residues 2-161 (ref. 48) were inserted into the third intracellular loop between residues Ala 301 and Ala 303, with only one residue Val 302 removed. To facilitate purification, an N-terminal Flag epitope was inserted after a signal peptide and a C-terminal deca-histidine tag was introduced. The final crystallization construct PAR1-T4L is shown in Supplementary Fig. 2 . The modified PAR1 was expressed in Sf9 cells using the pFastBac baculovirus system (Invitrogen). The ligand vorapaxar was added at 100 nM to the cells during expression. The cells were infected with baculovirus at 27 uC for 48 h before collection. To purify the receptor, infected cells were lysed by osmotic shock in low-salt buffer containing 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 100 nM vorapaxar and 2 mg ml 21 iodoacetamide. Iodoacetamide was used to alkylate reactive cysteines to prevent nonspecific oligomerization. The protein was further extracted from cell membranes using a glass dounce homogenizer in buffer containing 20 mM Tris-HCl, pH 7.5, 350 mM NaCl, 1% dodecyl maltoside (DDM), 0.03% cholesterol hemisuccinate (CHS), 0.2% sodium cholate, 10% glycerol, 2 mg ml 21 iodoacetamide and 100 nM vorapaxar. Cell debris was removed by high-speed centrifugation. From this point, 1 mM vorapaxar was added in all the following buffers used for purification. Nickel-NTA agarose resin was added to the supernatant after homogenization and stirred for 1 h at 4 uC. The resin was then washed three times in batch with buffer comprised of 20 mM HEPES, pH 7.5, 350 mM NaCl, 0.1% DDM, 0.02% CHS and 1 mM vorapaxar, and transferred to a glass column. The bound receptor was eluted with buffer containing 300 mM imidazole and loaded onto an anti-Flag M1 affinity column. After extensive washing with buffer comprised of 20 mM HEPES, pH 7.5, 350 mM NaCl, 0.1% DDM, 0.02% CHS, 1 mM vorapaxar and 2 mM Ca 21 , the receptor was eluted from M1 resin using the same buffer without Ca 21 but with 200 mg ml 21 Flag peptide and 5 mM EDTA. To remove extra N-terminal residues and the Flag epitope, TEV protease was added to the receptor and the cleavage reaction run at room temperature overnight. Size exclusion chromatography was used to obtain the final monodisperse receptor preparation. Purified PAR1-T4L was concentrated to 40-50 mg ml 21 using 100 kDa cut-off Vivaspin concentrators for crystallization. Crystallization. As for other T4L-fused GPCRs crystallized so far, in meso crystallization was used to obtain PAR1-T4L crystals 49, 50 . The protein was mixed with monoolein and cholesterol (10:1 by mass) using the two syringe mixing method by weight of 1:1.5 (protein:lipid). After a clear lipidic cubic phase formed, the mix was dispensed onto glass plates in 20-40 nl drops overlaid with 700 nl precipitant solution using a Gryphon LCP robot. Crystals appeared in two days in 0.1-0.2 M sodium chloride, 100 mM sodium phosphate, pH 6.0-6.5, 25-35% PEG300, and grew to full size after 1 week ( Supplementary Fig. 3) . Data collection and structure determination. Crystals were collected and frozen in liquid nitrogen. Date collection was performed at beamline 23-ID of GM/ CA@APS at the Advanced Photon Source. Microbeams of 10 or 20 mM diameter were used to acquire all diffraction data. Owing to radiation damage, only 5-20 degrees of rotation data were collected from each crystal. All data were processed with the HKL2000 package 51 . A 2.2-Å data set was obtained by merging diffraction data from 18 crystals. The space group was determined to be P2 1 2 1 2 1 . Molecular replacement was performed using the program Phaser 52 in Phenix 53 , with the CXCR4 structure (PDB accession 3ODU) as the search model. The seven-transmembrane helices without any loops, and the T4L in the CXCR4 structure, were used as independent search models. The initial structure model was completed and improved through iterative refinement in Phenix 53 and manual rebuilding of all the loops and several parts in the transmembrane region in Coot 54 . Model refinement in Phenix and manual adjustment in Coot was performed to improve the model. The final structure was determined at 2.2-Å resolution. The quality of the structure was assessed using Molprobity 55 . Data processing and structure refinement statistics are shown in Supplementary  Table 1 . Figures were prepared with PyMol 56 . Phosphoinositide hydrolysis assays and cell-surface expression level. The QuikChange site-directed mutagenesis kit (Agilent) was used to generate human PAR1 mutants and all mutants were fully sequenced. Cos7 cells were transiently transfected using Fugene HD with either empty vector or wild-type human PAR1 and mutants in the mammalian expression vector pBJ1 and signalling assays were performed as described in ref. 46 . In brief, Cos7 cells expressing wild-type or mutant human PAR1 were labelled with [ 3 H]-myoinositol, then incubated with vehicle or 100 nM vorapaxar in DMEM medium containing 0.1% BSA, 20 mM HEPES, 0.2% 2-hydroxypropyl-b-cyclodextrin (to retain vorapaxar in solution)
for 1 h at 37 uC. Agonist (100 mM SFLLRN or 10 nM thrombin for PAR1 or other PAR agonists as indicated) was added and incubation continued for 1 h. The total amount of accumulated [ 3 H]-inositol phosphates accumulated was determined as in ref. 46 . Cos7 cells transfected with empty vector had little response to PAR agonists, and treatment with vorapaxar alone did not affect phosphoinositide hydrolysis ( Supplementary Fig. 9A ).
Surface expression of receptors was measured as described in refs 13 and 16. Cos7 cells were transiently transfected with empty pBJ1 or pBJ1 directing expression of N-terminal Flag-tagged versions of wild-type human PAR1 or mutants. After 48 h, cells were washed once with serum-free medium containing 0.1% BSA and 20 mM HEPES, then incubated with 3 mg ml 21 Flag M1 antibody (Sigma) for 1 h at 4 uC in the same medium. The cells were then washed twice with PBS containing Ca 21 and Mg 21 to remove unbound antibody and fixed with 2% paraformaldehyde for 5 min. The cells were then washed twice with PBS with Ca 21 and Mg 21 , and incubated with goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody, washed and developed with one-step ABTS HRP substrate (Pierce). The absorbance at 405 nm was measured as indication of cell surface receptor expression levels. Platelet signalling assays. Washed human platelets were prepared and PAR1dependent responses were measured as described in ref. 57 . In brief, acid-citratedextrose anti-coagulated human blood samples (60 ml per donor) were obtained from AllCells. Blood was centrifuged without braking at 250g at 37 uC for 15 min. The upper platelet-rich plasma phase was collected, incubated at 37 uC for 10 min in the presence of prostacyclin (PGI 2 , 0.5 mM), and centrifuged at 2,200g for 15 min. The pellet was resuspended in complete Tyrode's solution (134 mM NaCl, 12 mM NaHCO 3 , 2.9 mM KCl, 0.34 mM Na 2 HPO 4 , 1.0 mM MgCl 2 , 10 mM HEPES, 0.9% (w/v) dextrose, pH 7.4) containing 2 mM CaCl 2 , 0.35% (w/v) bovine serum albumin (BSA), 10 U ml 21 heparin, and 0.5 mM PGI 2 . The platelet suspension was incubated for 10 min at 37 uC then centrifuged at 1,900g for 8 min. This wash step was repeated and the final pellet resuspended in Tyrode's buffer supplemented with BSA and 0.02 U ml 21 apyrase. Platelets were incubated at 37 uC for 30 min to allow recovery from the effects of PGI 2 , counted using a Hemavet FS950 (Drew Scientific) and diluted to 300,000 cells per microlitre in Tyrode's solution.
To antagonize PAR1, vorapaxar or vehicle (2% (w/v) 2-hydroxypropyl-bcyclodextrin in dimethylsulphoxide (DMSO)) were added to platelet suspensions that were then incubated for 1 h at 37 uC before addition of agonists. The final concentrations of 2-hydroxypropyl-b-cyclodextrin and DMSO in platelet suspensions were 0.002% and 0.1%, respectively. Where reversibility was evaluated, platelets were washed twice with Tyrode's buffer containing BSA and PGI 2 after vorapaxar treatment then diluted for cell activation assays as above.
For flow cytometric analysis of platelet activation, platelets suspended in Tyrode's solution containing 2 mM CaCl 2 , 0.35% BSA and 0.02 U ml 21 apyrase were incubated with agonist and antibody simultaneously. Fluor-conjugated antibodies directed against P-selectin (phycoerythrin (PE)-conjugate of AK-4; Ebiosciences; 1:25 dilution) and the activated conformation of integrin a IIb b 3 (FITC-conjugate of PAC-1, BD Biosciences; 1:25 dilution) were used. After 15 min at 37 uC, the platelet suspension was diluted with PBS and platelet-bound antibody measured using an Accuri C6 flow cytometer (Accuri). Samples from at least three different donors were analysed, each in triplicate. Molecular dynamics simulation methods. In all simulations, the receptor was embedded in a hydrated lipid bilayer with all atoms, including those in the lipids and water, represented explicitly. Simulations were performed on Anton 47 , a special-purpose computer designed to accelerate molecular dynamics simulations by orders of magnitude. System set-up and simulation protocol. Simulations of PAR1 were based on the crystal structure of the PAR1-vorapaxar complex. The crystallized construct has T4L inserted into ICL3 in place of residue 302. For the simulations, the T4L portion was omitted, and residue 302 was modelled in. The unresolved segment of ICL2 (residues 209-213) was also modelled in. Residues 209 and 213 were added manually, and residues 210-212 were modelled in using Prime (Schrödinger LLC). The Refine Loops tool in Prime, with default settings, was then used to refine residues 209-213.
The simulation of the MOR dimer was based on the crystal structure of MOR bound to the irreversible antagonist b-funaltrexamine (PDB accession 4DKL). Both monomers of the crystallographic dimer were included in the simulation, but b-funaltrexamine was deleted from the binding pocket. As with PAR1, the T4L sequence was omitted in our simulations. Side chains for residue Met 65 1.29 , Thr 67 1.31 , Lys 260 ICL3 and Arg 263 ICL3 were not fully resolved in the crystal structure, so they were modelled in by hand, with rotamers chosen to avoid any clashes with resolved residues.
For both PAR1 and MOR, hydrogens were added to the crystal structures using Maestro (Schrödinger LLC), as described in previous work 58 . Histidines were ARTICLE RESEARCH singly protonated on the epsilon nitrogen. All other titratable residues were left in their dominant protonation state for pH 7.0, except for Asp 367 7.49 in PAR1 and Asp 114 2.50 in MOR, which were protonated, and Asp 148 2.50 in PAR1, which was protonated in certain simulations. PAR1 was simulated both with and without the crystallographic sodium ion by Asp 148 2.50 ( Supplementary Table 2 ); Asp 148 2.50 was not protonated in simulations that included this ion, but was protonated otherwise. The conserved aspartate at position 2.50 is known to be protonated in rhodopsin 59 , and the residue at position 7.49 is most often an (uncharged) asparagine residue in family A GPCRs (the 'N' of the NPXXY motif).
Prepared protein structures were inserted into an equilibrated POPC bilayer as described previously 32 . Sodium and chloride ions were added to neutralize the net charge of the system and to create a 150-mM solution.
Simulations of the PAR1 receptor initially measured 88.9 3 88.9 3 88.7 Å and contained 174 lipid molecules, and approximately 13,152 water molecules, for a total of ,67,500 atoms. When the crystallographic sodium ion near Asp 148 2.50 was included, the simulation contained 32 sodium ions and 36 chloride ions. When the crystallographic sodium ion was not included, the system contained 31 sodium ions and 36 chloride ions. To simulate the unliganded PAR1 receptor, vorapaxar was deleted from the binding pocket. Simulations of the MOR dimer initially measured 100.0 3 100.0 3 89.0 Å and contained 204 lipid molecules, 19 sodium ions, 43 chloride ions, and approximately 16,654 water molecules, for a total of ,86,700 atoms.
All simulations were equilibrated using Anton in the NPT ensemble at 310 K (37 uC) and 10 5 Pa with 5 kcal mol 21 Å 22 harmonic position restraints applied to all non-hydrogen atoms of the protein and the ligand; these restraints were tapered off linearly over 50 ns. All bond lengths to hydrogen atoms were constrained using M-SHAKE 60 . A RESPA integrator 61 was used with a time step of 2 fs, and long-range electrostatics were computed every 6 fs. Production simulations were initiated from the final snapshot of the corresponding equilibration runs, with velocities sampled from the Boltzmann distribution at 310 K, using the same integration scheme, long-range electrostatics method, temperature and pressure. For PAR1, Van der Waals and short-range electrostatic interactions were cut-off at 10.3 Å and long-range electrostatic interactions were computed using the k-space Gaussian split Ewald method 62 with a 32 3 32 3 32 grid, s 5 2.27 Å , and s s 5 1.59 Å . For MOR, van der Waals and short-range electrostatic interactions were cut-off at 10.16 Å and long-range electrostatic interactions were computed using the k-space Gaussian split Ewald method with a 64 3 64 3 64 grid, s 5 2.25 Å , and s s 5 1.55 Å .
We performed two vorapaxar-bound PAR1 simulations and four unliganded PAR1 simulations, and results were consistent across each set. The two receptors in our MOR dimer simulation also exhibited consistent behaviour. The simulation protocol we followed has been validated in previous simulations of GPCRs 63, 64 . Nevertheless, it is possible that different behaviour might have been observed in even longer simulations, with different force field parameters, or with a different choice of simulation conditions. Force field parameters. We used the CHARMM27 parameter set for protein molecules and salt ions, with the CHARMM TIP3P water model 65 ; protein parameters incorporated CMAP terms 66 and modified charges on the Asp, Glu and Arg side chains 67 . We used a modified CHARMM lipid force field 68 . Force field parameters for vorapaxar were obtained from the CHARMM ParamChem web server 69 , version 0.9.6 b. Analysis protocols. Trajectory snapshots, each containing a record of all atom positions at a particular instant in time, were saved every 180 ps during production simulations. Time series data shown in Supplementary Fig. 11 were smoothed by applying a 9.9-ns (55-snapshot) running average. VMD was used to visualize trajectories 70 .
